ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
Epistemonikos ID: 3a4e23e2df42e4bda1acf905ddfc5066a16405b8
First added on: May 12, 2024